Fig. 5 | British Journal of Cancer

Fig. 5

From: Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

Fig. 5

Tumour regrowth occurred after 2 weeks of PLX4720 mono- or combination therapy and coincided with a. A dramatic decrease in CD8+ cytotoxic T cells, granzyme B staining, and no change in FoxP3+ T cells, compared to 1 week of treatment. Three weeks of combination treatment was associated with further decreases in CD8+ cytotoxic T cells, granzyme B staining, and a dramatic increase in FoxP3+ T cells. N = 4 mice per group, repeated twice

Back to article page